Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Lucid Diagnostics Inc. (LUCD : NSDQ)

• Company Description    Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. Lucid Diagnostics Inc. is based in NEW YORK. Number of Employees: 72

• Price / Volume Information    Yesterday's Closing Price: $1.09 Daily Weekly Monthly 20 Day Moving Average: 641,241 shares Shares Outstanding: 137.68 (millions) Market Capitalization: $150.07 (millions) Beta: 1.22 52 Week High: $1.80 52 Week Low: $0.78 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 2.83% 3.00% 12 Week -11.38% -12.81% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 360 MADISON AVENUE 25TH FLOOR - NEW YORK,NY 10017 USA ph: 917-813-1828 fax: - mjr@pavmed.com http://www.luciddx.com

• General Corporate Information    Officers Lishan Aklog - Chief Executive Officer & Chairman Stanley N. Lapidus - Vice Chairman & Director Dennis M. McGrath - Chief Financial Officer Debra J. White - Director James L. Cox - Director Peer Information Lucid Diagnostics Inc. (ABMD) Lucid Diagnostics Inc. (DMDS) Lucid Diagnostics Inc. (CPWY.) Lucid Diagnostics Inc. (EQUR) Lucid Diagnostics Inc. (ECIA) Lucid Diagnostics Inc. (FMS) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED INSTRUMENTS Sector: Medical CUSIP: 54948X109 SIC: 3841 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/23/26 Share - Related Items Shares Outstanding: 137.68 Most Recent Split Date: (:1) Beta: 1.22 Market Capitalization: $150.07 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.07 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.27 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/23/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 34.12 EPS Growth vs. Year Ago Period: 50.00% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: 3.33% vs. Previous Quarter: 4.13% ROE 12/31/25 - - 09/30/25 - - 06/30/25 - - ROA 12/31/25 - - 09/30/25 - -96.99 06/30/25 - -120.43 Current Ratio 12/31/25 - - 09/30/25 - 1.90 06/30/25 - 1.15 Quick Ratio 12/31/25 - - 09/30/25 - 1.88 06/30/25 - 1.13 Operating Margin 12/31/25 - - 09/30/25 - -856.47 06/30/25 - -861.63 Net Margin 12/31/25 - - 09/30/25 - -1,418.39 06/30/25 - -1,476.35 Pre-Tax Margin 12/31/25 - - 09/30/25 - -1,211.30 06/30/25 - -1,267.41 Book Value 12/31/25 - - 09/30/25 - -0.21 06/30/25 - -0.43 Inventory Turnover 12/31/25 - - 09/30/25 - 15.32 06/30/25 - 14.02 Debt-to-Equity 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©